Ketoconazole

證據等級: L5

預測適應症: 1 個

Ketoconazole: From Fungal Infections to Acne (Disease)

One-Sentence Summary

Ketoconazole is a broad-spectrum antifungal agent, historically used to treat fungal infections. The TxGNN model predicts it may be effective for Acne (Disease), with 1 clinical trial and 16 publications currently supporting this direction — most of the literature is preclinical/mechanistic rather than confirmatory clinical evidence.

Quick Overview

Item	Content
Original Indication	Fungal infections (antifungal agent) — detailed indication text not available in evidence pack
Predicted New Indication	Acne (Disease)
TxGNN Prediction Score	99.80%
Evidence Level	L4
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, ketoconazole is an imidazole-class antifungal agent, its efficacy in fungal infections has been proven, and mechanistically it may be applicable to acne through two pathways suggested by the literature: (1) direct inhibition of Propionibacterium acnes lipase activity, reducing the sebum breakdown products that trigger follicular inflammation, and (2) antifungal activity against Malassezia (Pityrosporum) species, which cause folliculitis that is frequently clinically misdiagnosed as acne vulgaris.

Acne vulgaris and fungal folliculitis share overlapping clinical presentations and, in some cases, overlapping microbial contributors (bacterial lipase activity, yeast overgrowth), which provides a plausible mechanistic bridge from an antifungal agent to an acne indication. However, this rationale is currently supported mainly by in vitro/mechanistic studies rather than dedicated clinical trials of ketoconazole in acne populations, so the strength of this link should be considered preliminary.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07237763	NA	Active, not recruiting	52	RCT comparing topical ketoconazole 2% cream vs. topical adapalene 2% cream in mild comedonal/papulopustular acne, assessing whether ketoconazole is an alternative to topical retinoids with fewer side effects and better compliance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28111792	2017	In vitro / Mechanistic	Microbiology and Immunology	Ketoconazole inhibits P. acnes lipase activity, the enzyme responsible for sebum metabolites that trigger skin inflammation, suggesting a potential alternative acne treatment
20045949	2010	In vitro	Biological & Pharmaceutical Bulletin	Azole antifungal agents, including ketoconazole, show in vitro activity against P. acnes isolated from acne vulgaris patients
8593718	1995	Case series	Clinical and Experimental Dermatology	Pityrosporum folliculitis is frequently misdiagnosed as acne vulgaris; describes diagnosis and therapeutic trials in 62 patients
8255067	1993	Review	The Keio Journal of Medicine	Reviews Pityrosporum ovale as an opportunistic pathogen linked to folliculitis and other skin conditions overlapping with acne presentations
8629828	1996	Case series	Archives of Dermatology	Neonatal facial papulopustular eruptions ("neonatal acne") associated with Malassezia furfur infection
23600337	2013	Review	FP Essentials	Reviews common infant skin rashes including neonatal acne, noting overlap with infectious/inflammatory follicular conditions
32872149	2020	Review	Pharmaceuticals (Basel)	Reviews adapalene (the active comparator in NCT07237763) as first-line acne therapy, providing context for the ketoconazole vs. adapalene trial
12566804	2003	Review	Dermatology (Basel)	Reviews systemic treatment options for moderate-to-severe acne, highlighting rising antibiotic resistance and need for alternative agents
19445767	2009	Review	BMJ Clinical Evidence	Reviews PCOS, noting acne as a common associated dermatologic manifestation of hyperandrogenism
8090657	1993	Review	Polski Tygodnik Lekarski	Reviews treatment of hyperandrogenic manifestations (including acne) in PCOS

Norway Market Information

Ketoconazole is currently not marketed in Norway; no authorization information is available in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Note: Detailed TFDA/manufacturer warnings, contraindications, and drug-drug interaction data are currently unavailable (flagged as a Blocking data gap, DG001), which prevents a full S1 safety evaluation for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for ketoconazole in acne currently consists of one small, non-Phase, not-yet-completed RCT and predominantly preclinical/mechanistic literature (in vitro enzyme inhibition, case series on fungal folliculitis misdiagnosed as acne). No completed Phase 2/3 RCTs exist, and critical safety data (TFDA warnings/contraindications) are missing, which blocks a proper S1 safety evaluation. The drug is also not currently marketed in Norway.

To proceed, the following is needed:

Obtain TFDA/manufacturer package insert warnings and contraindications (resolve blocking gap DG001)
Obtain detailed mechanism of action data from DrugBank (resolve gap DG002)
Await completion and results of NCT07237763
Identify or commission dedicated controlled trials of ketoconazole vs. standard acne therapies
Determine regulatory pathway/feasibility for Norway market entry if this indication is pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.